Dr James Watson
Contact information
Podcast interview
Data driven definitions of severe malaria

James studies severe malaria in African children, focusing on improving diagnostic accuracy. By analysing clinical data, he aims to distinguish malaria-related severe illness from other infections and estimate true mortality more reliably. His work supports faster diagnosis and treatment, ultimately reducing preventable child deaths in low-resource settings.
Research groups
James Watson
IDDO Associate Director
Clinical Therapeutics
I am a statistician interested in improving the treatment of infectious diseases of global health importance. My main work focuses on severe malaria, notably improving the definition of severe malaria in areas of high malaria transmission. We have estimated that a third of children diagnosed with severe malaria in high transmission settings in fact have another cause of severe illness.
I also work on other infectious diseases: I am an investigator and study statistician for PLATCOV, a platform trial characterising in vivo antiviral effects of repurposed or novel drugs for COVID-19; I am an investigator on the CHARM project which aims to develop a new methodology for the assessment of new antiparasitic drugs for the treatment of Chagas disease.
Causal pathways in severe malaria
Recent publications
Accurate Measurement of Viral Clearance in Early-Phase Antiviral Studies in Coronavirus Disease 2019.
Journal article
Wongnak P. et al, (2026), The Journal of infectious diseases, 233, e582 - e584
Pharmacometric evaluation of sulfadoxine-pyrimethamine- amodiaquine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda.
Journal article
Bonnington C. et al, (2025), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Probabilistic classification of late treatment failure in uncomplicated falciparum malaria.
Journal article
Mehra S. et al, (2025), Nature communications, 16
Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials
Journal article
Watson JA. et al, (2025), The Lancet Microbe, 6, 101156 - 101156
Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA)
Journal article
Assmus F. et al, (2025), PLOS Neglected Tropical Diseases, 19, e0013522 - e0013522